BLCM Bellicum Pharmaceuticals Inc

Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that senior management will present at three upcoming healthcare investor conferences.

Conference Details:

Event: 2017 Wells Fargo Securities Healthcare Conference Date/Time: Wednesday, September 6 at 3:00 p.m. EDTLocation: Boston, MA

Event: Ladenburg Thalmann 2017 Healthcare Conference Date/Time: Tuesday, September 26 at 12:00 p.m. EDTLocation: New York, NY

Event: Cantor Fitzgerald Global Healthcare ConferenceDate/Time: Wednesday, September 27 at 9:10 a.m. EDT Location: New York, NY 

A live webcast of the fireside chat at Wells Fargo as well as the presentation at Ladenburg Thalmann may be accessed from the News & Events section of the Bellicum website. Archived versions of the webcasts will be available for replay for at least two weeks following the events.

About Bellicum Pharmaceuticals Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.

Investors:
Bellicum Pharmaceuticals, Inc.
Alan Musso, CFO
832-384-1116
amusso@bellicum.com 

Media:
BMC Communications
Brad Miles
646-513-3125
bmiles@bmccommunications.com

Source: Bellicum Pharmaceuticals